Actin binding GFP allows 4D in vivo imaging of myofilament dynamics in the zebrafish heart and the identification of ErBB2 signaling as a remodeling factor of myofibril architecture

Circulation Research

Volumn 115, Issue 10, 2014, Pages 845-856

  Reischauer, Sven ^a,c   Arnaout, Rima ^b   Ramadass, Radhan ^c   Stainier, Didier Y R ^a,c  

^a Department of Biochemistry and Biophysics ^*  (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Cardiomyopathies; Erbb2 protein, human; Growth and development; Heart contractility; Myocardial contraction; Myofibrils; Sarcomeres

Indexed keywords

ACTIN; DESMIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; F ACTIN; GREEN FLUORESCENT PROTEIN; TROPOMYOSIN; TROPONIN C; TROPONIN T; VINCULIN; ERBB2 PROTEIN, HUMAN; PROTEIN BINDING;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; HEART; HEART ATRIUM; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE WALL; IMAGE ANALYSIS; IN VIVO STUDY; INTERMEDIATE FILAMENT; MUSCLE FIBRIL; MYOFILAMENT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SARCOMERE; SINGLE CELL ANALYSIS; TRANSGENIC ZEBRAFISH; AMINO ACID SEQUENCE; ANATOMY AND HISTOLOGY; ANIMAL; CELL CULTURE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; THREE DIMENSIONAL IMAGING; TIME; TRANSGENIC ANIMAL; ZEBRA FISH;

ACTINS; AMINO ACID SEQUENCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELLS, CULTURED; GREEN FLUORESCENT PROTEINS; HEART; IMAGING, THREE-DIMENSIONAL; MOLECULAR SEQUENCE DATA; MYOFIBRILS; PROTEIN BINDING; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TIME FACTORS; ZEBRAFISH;

EID: 84924848508     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304356     Document Type: Article

References (35)

1. Rakar S, Sinagra G, Di Lenarda A, Poletti A, Bussani R, Silvestri F, Camerini F. Epidemiology of dilated cardiomyopathy. A prospective post-mortem study of 5252 necropsies. The Heart Muscle Disease Study Group. Eur Heart J. 1997;18:117-123.
2. Baselga J. Current and planned clinical trials with trastuzumab (Herceptin). Semin Oncol. 2000;27:27-32.
3. Taylor MR, Carniel E, Mestroni L. Cardiomyopathy, familial dilated. Orphanet J Rare Dis. 2006;1:27.
4. Merlo M, Sinagra G, Carniel E, Slavov D, Zhu X, Barbati G, Spezzacatene A, Ramani F, Salcedo E, Di Lenarda A, Mestroni L, Taylor MR; Familial Cardiomyopathy Registry. Poor prognosis of rare sarcomeric gene variants in patients with dilated cardiomyopathy. Clin Transl Sci. 2013;6:424-428.
5. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531-547.
6. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J Jr, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002;8:459-465.
7. Ozcelik C, Erdmann B, Pilz B, Wettschureck N, Britsch S, Hübner N, Chien KR, Birchmeier C, Garratt AN. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci USA. 2002;99:8880-8885.
8. Beis D, Stainier DY. In vivo cell biology: following the zebrafsh trend. Trends Cell Biol. 2006;16:105-112.
9. Riedl J, Crevenna AH, Kessenbrock K, Yu JH, Neukirchen D, Bista M, Bradke F, Jenne D, Holak TA, Werb Z, Sixt M, Wedlich-Soldner R. Lifeact: a versatile marker to visualize F-actin. Nat Methods. 2008;5:605-607.
10. Andrechek ER, Hardy WR, Girgis-Gabardo AA, Perry RL, Butler R, Graham FL, Kahn RC, Rudnicki MA, Muller WJ. ErbB2 is required for muscle spindle and myoblast cell survival. Mol Cell Biol. 2002;22:4714-4722.
11. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol. 2001;3:785-792.
12. Heermann S, Schwab MH. Molecular control of Schwann cell migration along peripheral axons. Cell Adhes Migr. 2013;7:18-22.
13. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7:505-516.
14. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A. Studies of the HER-2/neu proto-onco-gene in human breast and ovarian cancer. Science. 1989;244:707-712.
15. Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.
16. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390-394.
17. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394-398.
18. Staudt DW, Liu J, Thorn KS, Stuurman N, Liebling M, Stainier DY. High-resolution imaging of cardiomyocyte behavior reveals two distinct steps in ventricular trabeculation. Development. 2014;141:585-593.
19. Liu J, Bressan M, Hassel D, Huisken J, Staudt D, Kikuchi K, Poss KD, Mikawa T, Stainier DYR. A dual role for ErbB2 signaling in cardiac tra-beculation. Dev Camb Engl. 2010;137:3867-3875.
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
21. Suster ML, Kikuta H, Urasaki A, Asakawa K, Kawakami K. Transgenesis in zebrafsh with the tol2 transposon system. Methods Mol Biol Clifton NJ. 2009;561:41-63.
22. Kashles O, Yarden Y, Fischer R, Ullrich A, Schlessinger J. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol. 1991;11:1454-1463.
23. Lyons DA, Pogoda HM, Voas MG, Woods IG, Diamond B, Nix R, Arana N, Jacobs J, Talbot WS. erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafsh. Curr Biol. 2005;15:513-524.
24. Mably JD, Mohideen MA, Burns CG, Chen JN, Fishman MC. heart of glass regulates the concentric growth of the heart in zebrafsh. Curr Biol. 2003;13:2138-2147.
25. Kaufmann A, Mickoleit M, Weber M, Huisken J. Multilayer mounting enables long-term imaging of zebrafsh development in a light sheet microscope. Development. 2012;139:3242-3247.
26. Liebling M, Forouhar AS, Gharib M, Fraser SE, Dickinson ME. Four-dimensional cardiac imaging in living embryos via postacquisition synchronization of nongated slice sequences. J Biomed Opt. 2005;10:054001.
27. Reischauer S, Levesque MP, Nüsslein-Volhard C, Sonawane M. Lgl2 executes its function as a tumor suppressor by regulating ErbB signaling in the zebrafsh epidermis. PLoS Genet. 2009;5:e1000720.
28. Marshall OJ. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR. Bioinforma Oxf Engl. 2004;20:2471-2472.
29. Sander V, Suñe G, Jopling C, Morera C, Izpisua Belmonte JC. Isolation and in vitro culture of primary cardiomyocytes from adult zebrafsh hearts. Nat Protoc. 2013;8:800-809.
30. Sehnert AJ, Huq A, Weinstein BM, Walker C, Fishman M, Stainier DY. Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat Genet. 2002;31:106-110.
31. Stainier DY, Fishman MC. Patterning the zebrafsh heart tube: acquisition of anteroposterior polarity. Dev Biol. 1992;153:91-101.
32. Peshkovsky C, Totong R, Yelon D. Dependence of cardiac trabecula-tion on neuregulin signaling and blood fow in zebrafsh. Dev Dyn. 2011;240:446-456.
33. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracycline-induced myofbrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation. 2002;105:1551-1554.
34. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R, Sawyer DB. Anthracyclines induce calpain-de-pendent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem. 2004;279:8290-8299.
35. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, Kelly RA, Sawyer DB. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 2003;35:1473-1479.